Claims

1. A compound of formula (I):



(I)

wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstitutedC_{1-6} alkyl;

R^2 is $(CH_2)_mR^3$ where m is 0 or 1;

or R^1 and R^2 together with N to which they are attached form an optionally substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R^3 is a 4- to 8- membered non-aromatic heterocyclyl group, a C_{3-8} cycloalkyl group, a straight or branched C_{1-10} alkyl, a C_{2-10}alkenyl, a C_{3-8}cycloalkenyl, a C_{2-10}alkynyl, or a C_{3-8}cycloalkynyl any of which can be unsubtituted or substituted or R^5;

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, or SO_2Me;

R^5 is



wherein p is 0, 1 or 2, and X is CH_2, O, or S;

R^6 is a substituted or unsubstituted (C_{1-6})alkyl or chloro and R^{10} is hydrogen or R^{10} is a substituted or unsubstituted (C_{1-6})alkyl or chloro and R^6 is hydrogen;

R^7 is OH, C_{1-6}alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$ or $SOqR^9$;

R^{8a} is H or C_{1-6}alkyl;

R^{8b} is H or C_{1-6}alkyl;

R^9 is C_{1-6}alkyl;

q is 0, 1 or 2;

or a pharmaceutically acceptable derivative thereof.

2. A compound as claimed in claim 1 of formula (Ia):



(Ia)

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstitutedC_{1-6} alkyl;

R^2 is $(CH_2)_mR^3$ where m is 0 or 1;

or R^1 and R^2 together with N to which they are attached form a non-aromatic heterocyclyl ring selected from azetidinyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, tetrahydropyridinyl, azapine, oxapine, azacyclooctanyl, azaoxacyclooctanyl and azathiacyclooctanyl, any of which can be unsubstituted or substituted with 1, 2 or 3 substituents selected from; C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, methylsulfonyl, $NR^{8a}R^{8b}$, CH_2phenyl, $NHCOCH_3$, (=O), $CONHCH_3$ and $NHSO_2CH_3$;

R^3 is 2- or 3- azetidinyl, oxetanyl, thioxetanyl, thioxetanyl-s-oxide, thioxetanyl-s,s-dioxide, dioxalanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiophenyl-s,s-dioxide, morpholinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, thiomorpholinyl, thiomorpholinyl-s,s-dioxide, tetrahydropyridinyl, dioxanyl, tetrahydro-thiopyran 1,1 dioxide, azapine, oxapine, azacyclooctanyl, azaoxacyclooctanyl, azathiacyclooctanyl, oxacylcooctanyl, thiacyclooctanyl, a C_{3-8} cycloalkyl group, a straight or branched C_{1-10} alkyl, a C_{2-10}alkenyl, a C_{3-8}cycloalkenyl, a C_{2-10}alkynyl, or a C_{3-8}cycloalkynyl or R^5; any of which can be unsubstituted or substituted with 1, 2 or 3 substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, methylsulfonyl, $NR^{8a}R^{8b}$, CH_2phenyl, $NHCOCH_3$, (=O), $CONHCH_3$ and $NHSO_2CH_3$;

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, or SO_2Me;

R^5 is



wherein p is 0, 1 or 2, and X is CH_2, O or S;

R^6 is a substituted or unsubstituted (C_{1-6})alkyl or chloro and R^{10} is hydrogen or R^{10} is a substituted or unsubstituted (C_{1-6})alkyl or chloro and R^6 is hydrogen;

R^7 is OH, C_{1-6}alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$ or $SOqR^9$;

R^{8a} is H or C_{1-6}alkyl;

R^{8b} is H or C_{1-6}alkyl;

R^9 is C_{1-6}alkyl;

R^{11} is C_{1-6} alkyl, halosubstitutedC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, C_{1-6}alkylsulfonyl group, $-CONH_2$, $-NHCOCH_3$, -COOH, halosubstituted C_{1-6} alkoxy $SO_2NR^{8a}R^{8b}$ or C_{1-6} alkynyl;

q is 0, 1 or 2;

d is 0,1, 2, or 3;
or a pharmaceutically acceptable derivative thereof.

3. A compound as claimed in claim 1 or 2 wherein R^1 is hydrogen.

4. A compound as claimed in any preceding claim wherein R^4 is C_{1-6} alkyl or hydrogen.

5. A compound as claimed in any preceding claim wherein R^6 is *t*-butyl, isopropyl or CF_3.

6. A pharmaceutical composition comprising a compound as claimed any preceding claim or a pharmaceutically acceptable derivative thereof .

7. A pharmaceutical composition as claimed in claim 6 further comprising a pharmaceutical carrier or diluent thereof.

8. A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in any one of claims 1 to 5 or a pharmaceutically acceptable derivative thereof.

9. A method of treatment as claimed in claim 8 wherein the condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.